Werewolf Therapeutics, Inc.
HOWL
$0.711
-$0.0816-10.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 1.14M | 742.00K | 1.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 1.14M | 742.00K | 1.50M |
| Cost of Revenue | 12.38M | 12.53M | 15.27M | 12.91M | 6.78M |
| Gross Profit | -12.38M | -12.53M | -14.13M | -12.17M | -5.28M |
| SG&A Expenses | 7.97M | 4.60M | 4.83M | 5.00M | 7.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.35M | 17.12M | 20.10M | 17.90M | 14.46M |
| Operating Income | -20.35M | -17.12M | -18.96M | -17.16M | -12.96M |
| Income Before Tax | -20.40M | -16.67M | -17.25M | -16.19M | -12.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.40M | -16.67M | -17.25M | -16.19M | -12.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.40M | -16.67M | -17.25M | -16.19M | -12.00M |
| EBIT | -20.35M | -17.12M | -18.96M | -17.16M | -12.96M |
| EBITDA | -19.91M | -16.67M | -18.51M | -16.70M | -12.50M |
| EPS Basic | -0.46 | -0.38 | -0.40 | -0.39 | -0.33 |
| Normalized Basic EPS | -0.29 | -0.24 | -0.24 | -0.24 | -0.21 |
| EPS Diluted | -0.46 | -0.38 | -0.43 | -0.39 | -0.33 |
| Normalized Diluted EPS | -0.29 | -0.24 | -0.24 | -0.24 | -0.21 |
| Average Basic Shares Outstanding | 44.48M | 43.70M | 43.52M | 41.61M | 36.57M |
| Average Diluted Shares Outstanding | 44.48M | 43.70M | 44.04M | 41.61M | 36.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
